Stable, high-expressing cell lines are a critical component in commercial manufacturing of therapeutic proteins and vaccines. But the time and cost of developing these lines is exacerbated by the ...
NEWARK, Calif.--(BUSINESS WIRE)--ATUM (formerly DNA2.0 Inc.), a pioneer in bioengineering solutions, announce the issuance of patent No. 10,041,077 by the U.S. Patent and Trademark Office (USPTO) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results